Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-08T02:16:04.297Z Has data issue: false hasContentIssue false

8 - AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA

Published online by Cambridge University Press:  11 July 2009

By
J.-L. Harousseau
Edited by
S. Vincent Rajkumar  and
Robert A. Kyle
S. Vincent Rajkumar
Affiliation:
Mayo Clinic, Minnesota
Robert A. Kyle
Affiliation:
Mayo Clinic, Minnesota
Get access

Summary

INTRODUCTION

Until now high-dose therapy (HDT) supported by Autologous Stem Cell Transplantation (ASCT) has been considered the standard of care for frontline therapy of multiple myeloma (MM) in younger patients with normal renal function, and MM is currently the first indication of ASCT.

However, the introduction of novel agents Thalidomide, bortezomib, and lenalidomide is changing the scenario in two ways. First, these agents can be added to HDT either before or after ASCT, with the objectives of increasing the complete remission (CR) rate and of prolonging first remission duration.

Second, the use of novel agents as frontline therapy in combination with either dexamethasone or alkylating agents yields CR rates and progression-free survival (PFS) rates that are comparable to those achieved with HDT. Therefore the role of ASCT is again a matter of debate: should it be used upfront or only as salvage treatment at progression in patients initially treated with novel agents?

AUTOLOGOUS STEM CELL TRANSPLANTATION IN MM. WHAT HAVE WE LEARNED IN THE PAST 25 YEARS?

The concept of dose intensity in MM

In 1983, Mc Elwain and Powles introduced the concept of HDT in MM. With a single infusion of high-dose intravenous melphalan, they obtained a high response rate including CR in nine patients with high-risk MM, which was in favor of a dose-response effect of melphalan. The results of this pioneer work were confirmed later in a larger study.

Type
Chapter
Information
Treatment of Multiple Myeloma and Related Disorders , pp. 86 - 100
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gratwohl, A, Baldomero, H, Frauendorfer, K, et al. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant 2007;online.Google ScholarPubMed
Harousseau, JL, Shaughessy, J, Richardson, P.Multiple myeloma. Hematology Am Soc Hematol Educ Program 2004;237–56.Google ScholarPubMed
Mc Elwain, TJ, Powles, RL.High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;16:822–4.CrossRefGoogle Scholar
Selby, PJ, Mc Elwain, TJ, Nandi, AC, et al. Multiple myeloma treated with high-dose intravenous melphalanBr J Haematol 1987;66:55–62.CrossRefGoogle ScholarPubMed
Barlogie, B, Hall, R, Zander, A, Dicke, K, Alexanian, R.High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986;67:1298–301.Google ScholarPubMed
Barlogie, B, Alexanian, R, Dicke, KA, et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987;70:869–72.Google ScholarPubMed
,Myeloma Trialists’ Collaborative group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832–42.CrossRefGoogle Scholar
Harousseau, JL, Attal, M.The role of autologous hematopoietic stem cell transplantationin multiple myeloma. Semin hematol 1997;34 (suppl 1):61–6.Google Scholar
Barlogie, B, Jagannath, S, Vesole, DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789–93.Google ScholarPubMed
Palumbo, A, Triolo, S, Argentino, C, et al. Dose-intensive melphalan with stem cell support is superior to standard treatment in elderly myeloma patients. Blood 1999;94:1248–53.Google ScholarPubMed
Lenhoff, S, Hjorth, M, Holmberg, E, et al. Impact of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000;95:7–11.Google ScholarPubMed
Blade, J, San Miguel, JF, Fontanillas, M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. Blood 1996;14:2167–73.Google Scholar
Attal, M, Harousseau, JL, Stoppa, AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91–7.CrossRefGoogle ScholarPubMed
Child, JA, Morgan, GJ, Davies, FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–83.CrossRefGoogle ScholarPubMed
Fermand, JP, Ravaud, P, Chevret, S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: upfront or rescue treatment? Results of a multicenter sequential randomized trial. Blood 1998;92:3131–6.Google Scholar
Palumbo, A, Bringhen, S, Petrucci, MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50–70: results of a randomized controlled trial. Blood 2004;104:3052–7.CrossRefGoogle Scholar
Blade, J, Rosinol, L, Sureda, A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Blood 2005;106:3755–9.CrossRefGoogle ScholarPubMed
Fermand, JP, Katsahian, S, Divine, M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227–33.CrossRefGoogle Scholar
Barlogie, B, Kyle, RA, Anderson, KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of Phase III US Intergroup trial S9321. J Clin Oncol 2006;24:929–36.CrossRefGoogle ScholarPubMed
Alexanian, R, Dimopoulos, MA, Hester, J, Delasalle, K, Champlin, R.Early myeloablative therapy for multiple myeloma. Blood 1994;84:4278–82.Google ScholarPubMed
Rajkumar, SV, Fonseca, R, Lacy, MQ, et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 1999;23:1267–72.CrossRefGoogle ScholarPubMed
Koreth, J, Cutler, CS, Djulbegovic, B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13:183–96.CrossRefGoogle ScholarPubMed
Gertz, M, Lacy, MQ, Inwards, DJ, et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 2000;26:45–50.CrossRefGoogle ScholarPubMed
Attal, M, Harousseau, JL, Facon, T, et al. Intergroupe Francophone du Myelome: single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495–502.CrossRefGoogle ScholarPubMed
Harousseau, JL, Attal, M, Moreau, P, et al. The prognostic impact of complete remission plus very good partial remission in a double-transplantation program for newly diagnosed multiple myeloma. Blood 2006;108:877a (abstract).Google Scholar
Vesole, DH, Tricot, G, Jagannath, S, et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996;88: 838–47.Google ScholarPubMed
Fassas, A, Shaughnessy, J, Barlogie, B.Cure of myeloma: hype or reality? Bone Marrow Transplant 2005;35:215–24.CrossRefGoogle ScholarPubMed
Lahuerta, JJ, Martinez-Lopez, J, Serna, J, et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000;109:438–46.CrossRefGoogle Scholar
Wang, M, Delasalle, K, Thomas, S, Giralt, S, Alexanian, R.Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood 2006;108:123a (abstract).Google Scholar
Lenhoff, S, Hjorth, M, Turesson, I, et al. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006;01:1228–33.Google Scholar
Sonneveld, P, Holt, B, Segeren, CM, et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term results of the Dutch Cooperative group HOvon 24 trial. Haematologica 2007;92:928–35.CrossRefGoogle ScholarPubMed
Pineda-Roman, M, Bolejack, V, Arzoumian, V, et al. Complete response in myeloma extends survival, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007;136:393–9.CrossRefGoogle ScholarPubMed
Rhee, F, Bolejack, V, Hollmig, K, et al. High serum-free light chain levels and their rapid reduction in response define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007;110:827–32.CrossRefGoogle ScholarPubMed
Rajkumar, SV, Fonseca, R, Dispenzieri, A, et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000;26:979–83.CrossRefGoogle ScholarPubMed
Durie, BG, Jacobson, J, Barlogie, B, Crowley, J.Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in SWOG chemotherapy trials. J Clin Oncol 2004;22(10):1857–63.CrossRefGoogle Scholar
Velde, HJK, Liu, X, Chen, G, Cakana, A, Draedt, W, Bayssas, M.Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92:1399–406.CrossRefGoogle ScholarPubMed
Kyle, RA, Leong, T, Li, S, et al. Complete response in multiple myeloma. Clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 2006;106:1958–66.CrossRefGoogle Scholar
Richardson, PG, Sonneveld, P, Schuster, M, et al. Extended follow-up of a Phase III trial in relapsed multiple myeloma: final time-to-event results of the Apex trial. Blood 2007;110:3557–60.CrossRefGoogle ScholarPubMed
Harousseau, JL, Weber, D, Dimopoulos, M, et al. Relapsed/Refractory multiple myeloma patients treated with lenalidomide/dexamethasone who achieve a complete or near complete response have longer overall survival than patients achieving a partial response. Blood 2007;110:1052a (abstract).Google Scholar
Harousseau, JL. Role of stem cell transplantation. Hematol Oncol Clin North Am 2007;21:1157–74.
Blade, J, Samson, D, Reece, D, et al. Criteria for evaluating disease response and progression in patients treated with high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998;102:1115–23.CrossRefGoogle Scholar
Durie, BG, Harousseau, JL, San Miguel, JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73.CrossRefGoogle ScholarPubMed
Harousseau, JL.Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma. Haematologica 1999;84:548–53.Google ScholarPubMed
Tricot, G, Jagannath, S, Vesole, D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favourable variables for rapid engraftment in 225 patients. Blood 1996;85:588–96.Google Scholar
Gertz, MA, Witzig, TE, Pineda, AA, et al. Monoclonal plasma cells in the blood stem-cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone marrow Transplant 1999;19:337–42.CrossRefGoogle Scholar
Cunningham, D, PAZ-Ares, L, Milan, S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759–63.CrossRefGoogle ScholarPubMed
Lopez-Perez, R, Garcia-Sanz, R, Gonzalez, D, et al. The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia 2000;14:1493–9.CrossRefGoogle ScholarPubMed
Moreau, P, Facon, T, Attal, M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140mg/m2 melphalan as conditioning regimen for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 trial. Blood 2002;99:731–5.CrossRefGoogle Scholar
Philips, GL, Meisenberg, BR, Reecede, , et al. Activity of single-agent melphalan 220 to 300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone marrow Transplant 2004;33:781–7.CrossRefGoogle Scholar
Moreau, P, Milpied, N, Mahe, B, et al. Melphalan 220 mg/m2 followed by peripheral stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999;23:1003–6.CrossRefGoogle ScholarPubMed
Moreau, P, Hulin, C, Garban, F, et al. Tandem autologous stem cell transplantation in high risk-de novo multiple myeloma: final results of the prospective and randomized IFM 99–04 protocol. Blood 2006;107:397–403.CrossRefGoogle ScholarPubMed
Giralt, S, Bensinger, W, Goodman, M, et al. 166Ho-DOTMP plus melphalan followed by peripheral blod stem cell transplantation in patients with multiple myeloma. Blood 2003;102:2684–91.CrossRefGoogle Scholar
Carreras, E, Rosinol, L, Terol, MF, et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007;13:1448–54.CrossRefGoogle ScholarPubMed
Harousseau, JL, Milpied, N, Laporte, JP, et al. Double intensive therapy in high-risk multpile myeloma. Blood 1992;79:2827–33.Google Scholar
Barlogie, B, Jagannath, S, Desikan, KR, et al. Total therapy with tandem autotransplants for newly diagnosed multiple myeloma. Blood 1999;93:55–65.Google Scholar
Cavo, M, Tosi, P, Zamagni, E, et al. Prospective randomized study of single compared with double autologous stem cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434–41.CrossRefGoogle ScholarPubMed
Siegel, DS, Desikan, KR, Mehta, J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93:51–4.Google Scholar
Jantunen, E, Juittinen, T, Penttila, K, et al. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>65 years) myeloma patients: comparison with younger patients treated with the same protocol. Bone marrow Transplant 2006;37:917–22.CrossRefGoogle ScholarPubMed
Badros, A, Barlogie, B, Siegel, D, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001;114:1248–53.Google ScholarPubMed
Facont, , Mary, JY, Hulin, C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomized trial. Lancet 2007;370:1209–18.CrossRefGoogle Scholar
Badros, A, Barlogie, B, Siegel, D, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114:822–9.CrossRefGoogle ScholarPubMed
Tosi, P, Zamagni, E, Ronconi, S, et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and renal failure. Leukemia 2000;14:1310–3.CrossRefGoogle ScholarPubMed
San Miguel, J, Lahuerta, JJ, Garcia-Sanz, R, et al. Are myeloma patients with renal failure candidate for autologous transplantation. The Hematology Journal 2000;1:28–36.CrossRefGoogle Scholar
Desikan, R, Barlogie, B, Sawyer, J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remission and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;95:4008–10.Google ScholarPubMed
Facon, T, Avet-Loiseau, H, Guillerm, G, et al. Chromosome 13 abnormalities identified by Fish analysis and serum β2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566–71.CrossRefGoogle ScholarPubMed
Tricot, G, Spencer, T, Sawyer, J, et al. Predicting long-term (>5years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002;116;211–7.CrossRefGoogle Scholar
Shaughnessy, J, Jacobson, J, Sawyer, J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy ensures long-term survival in multiple myeloma treated with Total Therapy 1: interpretation in the context of global gene expression. Blood 2003;101:3849–56.CrossRefGoogle Scholar
Fassas, AT, Spencer, T, Sawyer, J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002;118:1041–7.CrossRefGoogle ScholarPubMed
Chang, H, Sloan, S, Li, D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125:64–8.CrossRefGoogle Scholar
Gertz, M, Lacy, MQ, Dispenzieri, A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;125:2837–40.CrossRefGoogle Scholar
Jaksic, W, Trudel, S, Chang, H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005;105:7069–73.CrossRefGoogle Scholar
Chang, H, Qi, C, Yi, QL, et al. P53 gene deletion detected by fluorescence in situ hybridisation is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005;105:358–60.CrossRefGoogle ScholarPubMed
Avet-Loiseau, H, Attal, M, Moreau, P, et al. Genetic abnormalities and survival in multiple myeloma:the experience of the Intergroupe Francophone du Myeloma. Blood 2007;109:3489–95.CrossRefGoogle ScholarPubMed
Kumar, S, Lacy, MQ, Dispenzieri, A, et al. Single agent dexamethasone for prestem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 2004;34:485–90.CrossRefGoogle Scholar
Rajkumar, SV, Blood, E, Vesole, D, et al. Phase III clinical trial of Thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–6.CrossRefGoogle ScholarPubMed
Cavo, M, Zamagni, E, Tosi, P, et al. Superiority of thalidomide and dexamethsone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35–9.CrossRefGoogle Scholar
Macro, M, Divine, M, Uzunban, Y, et al. Dexamethasone + thalidomide compared to VAD as pretransplant treatment in newly diagnosed multiple myeloma: a randomized trial. Blood 2006;108:22a (abstract).Google Scholar
Lokhorst, HM, Schidt-Wolf, I, Sonneveld, P, et al. Thalidomide in induction treatment increases the very good partial remission rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008;93:124–7.CrossRefGoogle ScholarPubMed
Breitkreutz, I, Lokhorst, HM, Raab, MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yieldLeukemia 2007;21:1294–9.CrossRefGoogle ScholarPubMed
Morgan, GJ, Davies, FE, Owen, RG, et al. Thalidomide combinations improve response rates: results from the MRC IX study. Blood 2007;110:1051a (abstract).Google Scholar
Jagannath, S, Durie, B, Wolf, J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776–83.CrossRefGoogle ScholarPubMed
Harousseau, JL, Attal, M, Leleu, X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica 2006;91:1498–505.Google ScholarPubMed
Rosinol, L, Oriol, A, Mateos, MV, et al. Phase II Pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007;25:4452–8.CrossRefGoogle ScholarPubMed
Harousseau, JL, Mathiot, C, Attal, M, et al. Velcade/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: updated results of the IFM 2005/01 trial. Blood 2007;110:139a (abstract).Google Scholar
Attal, M, Harousseau, JL, Leyvraz, S, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006;15:3289–94.CrossRefGoogle Scholar
Oakervee, R, Pollat, R, Curry, N, et al. PAD combination (PS341, doxorubicin and dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776–83.CrossRefGoogle Scholar
Popat, R, Oakervee, HE, Curry, N, et al. Reduced dose PAD for previously untreated patients with multiple myeloma. Blood 2005;106:717a (abstract).Google Scholar
Wang, M, Giralt, S, Delasale, K, Handy, B, Alexanian, R.Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007;12:235–9.CrossRefGoogle ScholarPubMed
Cavo, M, Patriarca, F, Tacchetti, P, et al. Bortezomib-thalidomide-dexamethasone vs thalidomide-dexamethasone in preparation for autologous stem-cell transplantation in newly diagnosed multiple myeloma. Blood 2007;110:30a.Google Scholar
Lacy, MQ, Gertz, MA, Dispenzieri, A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179–84.CrossRefGoogle ScholarPubMed
Rajkumar, SV, Jacobus, S, Callander, N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E403): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 2007;110:31a (abstract).Google Scholar
Kumar, S, Dispenzieri, A, Lacy, MQ, et al. Impact of lenalidomide on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Leukemia 2007;21:2035–42.CrossRefGoogle Scholar
Mazumder, A, Kaufman, J, Niesvizky, R, Lonial, S, Vesole, D, Jagannath, S.Effect of lenalidomide on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008;22:1280–1.CrossRefGoogle ScholarPubMed
Richardson, P, Jagannath, S, Raje, N, et al. Lenalidomide, bortezomib, and dexamethasone as frontline therapy for patients with multiple myeloma: preliminary results of a Phase ½ study. Blood 2007;110:63a (abstract).Google Scholar
Hollmig, K, Stover, J, Talamo, G, et al. Addition of bortezomib to high dose melphalan as en effective conditioning regimen with autologous stem cell support in multiple myeloma. Blood 2004;103:266a (abstract).Google Scholar
Attal, M, Harousseau, JL.Role of autologous stem-cell transplantation in multiple myeloma. Best Practice & Research. Clin Haematol 2007;20:747–59.Google Scholar
Cunningham, D, Powles, R, Malpas, JS, et al. A randomized trial of maintenance therapy with intron A following high dose melphalan and ABMT in myeloma. Br J Haematol 1998;102:195–202.CrossRefGoogle Scholar
Stewart, AK, Chen, CI, Howson-Jan, K, et al. Results of a multicenter randomized trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004;10:8170–6.CrossRefGoogle ScholarPubMed
Brinker, BT, Walker, EK, Leong, T, et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 2006;106:2171–80.CrossRefGoogle ScholarPubMed
Barlogie, B, Tricot, G, Anaissie, E, et al. Thalidomide and hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021–30.CrossRefGoogle ScholarPubMed
Abdelkefi, A, Ladeb, S, Torjman, L, et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008;111:1805–1810.CrossRefGoogle ScholarPubMed
Spencer, A, Prince, HM, Roberts, A, et al. Thalidomide improves survival when used following ASCT. Haematologica 2007; 92:41–2 (abstract).Google Scholar
Singhal, S, Mehta, J, Desikan, R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–71.CrossRefGoogle ScholarPubMed
Jagannath, S, Richardson, PG, Sonneveld, P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2.3 trials. Leukemia 2007;21:151–7.CrossRefGoogle Scholar
Sagaster, V, Ludwig, H, Kaufmann, H, et al. Bortezomib is relapsed multiple myeloma: response rates and duration are independent of a chromosome 13q- deletion. Leukemia 2007;21:164–8.CrossRefGoogle ScholarPubMed
Bahlis, NJ, Mansoor, B, Lategan, JC, et al. Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14) : MM016 trial. Blood 2006;108:1016a (abstract).Google Scholar
Palumbo, A, Bringhen, S, Caravita, T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 2006;367:825–31.CrossRefGoogle Scholar
Mateos, MV, Hernandez, JM, Hernandez, MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase ½ study. Blood 2006;108:2165–72.CrossRefGoogle ScholarPubMed
San Miguel, JF, Schlag, R, Khuageva, N, et al. MMY-3002: a Phase III study comparing bortezomib-melphalan-prednisone with melphalan-prednisone in newly diagnosed multiple myeloma. Blood 2207;110:31a (abstract).Google Scholar
Palumbo, A, Falco, P, Corradini, P, et al. Melphalan, prednisone and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459–65.CrossRefGoogle Scholar
Barlogie, B, Anaissie, E, Rhee, F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176–85.CrossRefGoogle ScholarPubMed
Ladetto, M, Pagliano, G, Avonto, I, et al. Consolidation with bortezomib, thalidomide and dexamethasone induces molecular remissions in autografted multiple myeloma patients. Blood 2007;110:163a (abstract).Google Scholar
Barlogie, B, Tricot, GJ, Rhee, F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006;135:158–64.CrossRefGoogle ScholarPubMed
Bergsagel, PL.Individualizing therapy using molecular markers in multiple myeloma. Clin Lymphoma Myeloma 2007;(suppl 4): S170–4.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×